We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Still Anticipates Conclusive Vaccine Data by End of Year if Trials Resume
AstraZeneca Still Anticipates Conclusive Vaccine Data by End of Year if Trials Resume
As long as a safety review of an AstraZeneca COVID-19 trial that’s been paused due to an illness allows the trial to resume, the drugmaker expects to stay on track and submit its vaccine candidate for regulatory approval by the end of the year.